Related Experiment Video

Updated: May 1, 2026

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

2.6K

Engineered repressors are potent inhibitors of androgen receptor activity

Greg N Brooke1, Sue M Powell, Derek N Lavery

  • 1Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine, Imperial College London, W12 0NN, UK.

Oncotarget
|March 25, 2014
PubMed

Insights

Researchers developed novel engineered repressors to inhibit the Androgen Receptor (AR) pathway, showing potent prostate cancer cell growth inhibition. These repressors are effective even when conventional therapies fail due to AR mutation or altered cofactor levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Prostate cancer growth relies on the Androgen Receptor (AR) pathway.
  • Current AR-targeted therapies are effective initially but tumors progress to castrate-resistant prostate cancer (CRPC) within 2 years.
  • The AR remains a critical target in CRPC.

Purpose of the Study:

  • To develop a novel method for inhibiting AR activity in prostate cancer.
  • To investigate the efficacy of engineered repressors against AR in CRPC.
  • To overcome therapeutic resistance mechanisms in prostate cancer.

Main Methods:

  • Designing engineered repressors by fusing AR-binding motifs to repression domains.
  • Testing the inhibitory effects of engineered repressors on AR activity.
  • Evaluating the impact of engineered repressors on prostate cancer cell growth in vitro.
  • Assessing efficacy under conditions mimicking therapeutic resistance (AR mutation, altered cofactors).

Main Results:

  • Engineered repressors potently inhibit AR activity.
  • These novel inhibitors significantly reduce prostate cancer cell growth.
  • Engineered repressors demonstrate efficacy against AR even with mutations or altered cofactor levels, conditions where conventional therapies fail.

Conclusions:

  • Engineered repressors represent a promising novel therapeutic strategy for prostate cancer, including CRPC.
  • This approach offers a potential solution to overcome resistance to current AR-targeted therapies.
  • Targeting the AR ligand-binding domain with engineered repressors is a viable strategy for advanced prostate cancer treatment.

More Related Videos

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers10:28

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers

Published on: September 20, 2018

6.1K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

11.9K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.1K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.0K
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

2.3K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K